One group attempted to improve their previous dose-escalation study of HER2 CAR-T cells by using a combination of Cy/Flu lymphodepletion before HER2 CAR-T administration in children with refractory or metastatic osteosarcoma, RMS, and synovial sarcoma (NCT00902044). This evidence concerns the gene ERBB2 and synovial sarcoma.